** Shares of drugmaker EyePoint Pharmaceuticals EYPT.O rise ~11% to $8.47
** EYPT says its drug, Duravyu, met the main goal in mid-stage trial for the treatment of diabetic macular edema, a condition where fluid builds up in the central part of the retina due to damaged blood vessels
** The main goal was to evaluate if the drug could reduce the frequency of injections needed to treat the condition compared to the standard treatment, aflibercept
** 2.7 mg dose of Duravyu helped 73% of patients avoid extra injections, compared to 50% of patients treated with aflibercept - EYPT
** Co plans to initiate a late-stage non-inferiority trial for the drug by the end of 2025
** EYPT fell ~67% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。